BREVAGen Breast Cancer Test Launched
Jun 20, 2011
A new genetic testing service from Genetic Technologies Limited has been announced, called BREVAGen.
The new test looks at single nucleotide polymorphisms, otherwise known as SNPs, in order to determine an individual's risk of breast cancer.
The test takes about two to three weeks to yield results and involves cheek swabs that are the source of the genetic samples. Women's breast cancer clinics will receive the BREVAGen tests.
According to the chief of the company, this is one part of a large scale cancer initiative.
"The US launch of BREVAGen is the culmination of substantial investment in development encompassing large scale genomic investigations and substantial support in medical literature. It is the first phase of the company's five year strategy to build a global cancer diagnostics business," said Dr. Paul MacLeman, the CEO of the company.
According to the American Cancer Society, more than 200,000 women were newly diagnosed with the disease last year in the U.S., making breast cancer the second most common cancer among women, after skin cancer.